The Untold Story of the Longest Persisting CAR-T Cells in CLL
A deep dive into how CAR-T cells evolved in 2 patients with chronic lymphocytic leukemia who have had the longest complete remissions to date.
Hematologic Cancers
Follicular Lymphoma With Extranodal Disease Only: When to Suspect Systemic Disease
Follicular lymphoma manifesting with skin involvement only is considered to be a more aggressive disease than PCFCL.
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
The Confounding Case of Venetoclax in Multiple Myeloma
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo.
Similar Health Care Costs in Older Patients With AML Regardless of Induction Intensity
A similar number of transfusions were required in older patients with AML receiving intensive induction therapy versus single-agent azacitadine or decitabine.
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
Predicting Survival of Certain Subgroups of Patients With AML Following Allogeneic SCT
Based on the results of this study, a new risk stratification system was developed to facilitate prediction of posttransplant survival in patients with AML-MDC.
Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.
Single-Agent Acalabrutinib Meets Primary End Point of Phase 3 Study in R/R CLL
A phase 3 study of single-agent acalabrutinib versus rituximab plus idelasib or bendamustine in RR/CLL will be closed early due to favorable results at interim analysis.
Next post in Chronic Lymphocytic Leukemia
